Jubilant Life Sciences has surged 16% to Rs 88.50 on reports that the company may delist its equity shares from Indian bourses.
The stock opened at Rs 79.60 and hit a high of Rs 89.50 on the National Stock Exchange (NSE). A combined 3.3 million shares have already changed hands on the counter till 1430 hours against an average sub one million shares that were traded daily in past two weeks on both the exchanges.
Shares of a global pharmaceutical and life sciences firm that manufactures and supplies active pharmaceutical ingredients, generics and life science ingredients currently listed on the BSE and NSE.
“Jubilant Life Sciences aimed to raise $150-200 million through the initial public offering, might soon list itself on the New York Stock Exchange (NYSE),” the Business Standard report suggests.
Meanwhile, the stock has rallied 18% in past three days after the company said it has received ANDA approvals for Bupropion Hydrochloride from US FDA.
The current total market size of these products as per IMS is $518 million per annum. The company expects to launch these products in Q3 FY14, Jubilant Life Sciences said in a statement.
The stock opened at Rs 79.60 and hit a high of Rs 89.50 on the National Stock Exchange (NSE). A combined 3.3 million shares have already changed hands on the counter till 1430 hours against an average sub one million shares that were traded daily in past two weeks on both the exchanges.
Shares of a global pharmaceutical and life sciences firm that manufactures and supplies active pharmaceutical ingredients, generics and life science ingredients currently listed on the BSE and NSE.
“Jubilant Life Sciences aimed to raise $150-200 million through the initial public offering, might soon list itself on the New York Stock Exchange (NYSE),” the Business Standard report suggests.
Meanwhile, the stock has rallied 18% in past three days after the company said it has received ANDA approvals for Bupropion Hydrochloride from US FDA.
The current total market size of these products as per IMS is $518 million per annum. The company expects to launch these products in Q3 FY14, Jubilant Life Sciences said in a statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%